Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
DomainIon_trans_dom

TRPM6 KCNS1

1.09e-02114262IPR005821
DomainIon_trans

TRPM6 KCNS1

1.09e-02114262PF00520
InteractionLCN6 interactions

BMP7 CHPF2 FOXRED2 ART5

1.85e-0667274int:LCN6
InteractionFSTL4 interactions

CUL3 CHPF2 FOXRED2

1.25e-0534273int:FSTL4
DrugPhenelzine sulfate [156-51-4]; Down 200; 17uM; MCF7; HT_HG-U133A

ZFHX2 KCNS1 BMP7 SBF1 ERN2

3.35e-061992752319_DN
DrugAztreonam [78110-38-0]; Down 200; 9.2uM; MCF7; HT_HG-U133A

ZFHX2 CHPF2 FOXRED2 SLC4A4 ERN2

3.35e-061992755535_DN
DrugMethylatropine nitrate [52-88-0]; Down 200; 11uM; HL60; HT_HG-U133A

CUL3 KCNS1 SLC4A4 ERN2

7.54e-051932743116_DN
DrugOxyphenbutazone [129-20-4]; Down 200; 12.4uM; HL60; HT_HG-U133A

KCNS1 FOXRED2 SBF1 ERN2

7.69e-051942746160_DN
DrugMafenide hydrochloride [138-37-4]; Down 200; 18uM; HL60; HG-U133A

KCNS1 BMP7 CHPF2 SLC4A4

7.85e-051952741441_DN
Drugtroglitazone; Down 200; 10uM; HL60; HT_HG-U133A

KCNS1 BMP7 FOXRED2 ERN2

7.85e-051952746191_DN
DrugPseudopelletierine hydrochloride [6164-62-1]; Up 200; 21uM; PC3; HT_HG-U133A

ZFHX2 KCNS1 DMBT1 SLC4A4

8.00e-051962745828_UP
DrugLY294002; Down 200; 0.1uM; MCF7; HG-U133A

BMP7 CHPF2 SLC4A4 ERN2

8.16e-05197274424_DN
Drugalpha-estradiol; Down 200; 0.01uM; HL60; HT_HG-U133A

CUL3 BMP7 FOXRED2 SBF1

8.16e-051972746169_DN
DrugOxprenolol hydrochloride [6452-73-9]; Down 200; 13.2uM; HL60; HT_HG-U133A

CUL3 KCNS1 FOXRED2 SLC4A4

8.16e-051972746145_DN
DrugAminopurine, 6-benzyl [1214-39-7]; Up 200; 17.8uM; HL60; HT_HG-U133A

ZFHX2 KCNS1 BMP7 FOXRED2

8.16e-051972742351_UP
DrugMK-886; Down 200; 1uM; MCF7; HG-U133A

BMP7 TMEM39A SBF1 ERN2

8.16e-05197274601_DN
DrugFolinic acid calcium salt [6035-45-6]; Down 200; 7.8uM; HL60; HT_HG-U133A

FOXRED2 SLC4A4 SBF1 ERN2

8.32e-051982742579_DN
DrugXylometazoline hydrochloride [1218-35-5]; Up 200; 14.2uM; MCF7; HT_HG-U133A

CUL3 KCNS1 FOXRED2 SBF1

8.49e-051992747020_UP
DrugRauwolscine hydrochloride [6211-32-1]; Down 200; 10.2uM; MCF7; HT_HG-U133A

BMP7 CHPF2 SLC4A4 ERN2

8.49e-051992742778_DN
DrugCimetidine [51481-61-9]; Up 200; 15.8uM; HL60; HG-U133A

KCNS1 BMP7 CEP76 DMBT1

8.49e-051992741964_UP
DrugCyclopenthiazide [742-20-1]; Down 200; 10.6uM; HL60; HT_HG-U133A

ZFHX2 KCNS1 SLC4A4 ERN2

8.65e-052002742905_DN
Diseaseovarian carcinoma (is_marker_for)

BMP7 LETMD1

2.37e-0428242DOID:4001 (is_marker_for)
DiseaseJT interval

ZNF579 SLC4A4 RSKR

1.04e-03248243EFO_0007885
Disease3-hydroxypropylmercapturic acid measurement

TRPM6 BMP7 ERN2

2.83e-03352243EFO_0007014
DiseaseQT interval

ZNF579 SLC4A4 RSKR

8.99e-03534243EFO_0004682
Diseasebreast cancer (is_marker_for)

BMP7 LETMD1

9.86e-03185242DOID:1612 (is_marker_for)

Protein segments in the cluster

PeptideGeneStartEntry
FPIHFVYRNARRAFA

CEP76

596

Q8TAP6
FFHPRYHHREFRFDL

BMP7

146

P18075
HPFFYRRHITLRLGA

PTGDR

136

Q13258
YHRFLGRHFPRFYVL

LETMD1

71

Q6P1Q0
YFTNRFPRLLLHTHR

ERN2

881

Q76MJ5
GQHFLHFRYRLPLSH

LGALS12

151

Q96DT0
RRGSHPYIDFRIFHS

PDE7A

81

Q13946
FYFLRSLHRNLLHNP

FBXO44

71

Q9H4M3
RLRYLHHFQVHPFFR

RSKR

346

Q96LW2
LLRAPFRCYHFIFHS

MMAA

16

Q8IVH4
RHPGFFLSLLHFYRT

KCNS1

106

Q96KK3
DPRLLFRHYSRAYFP

FOXRED2

106

Q8IWF2
FLGYHHVSRRFRTFL

SBF1

1511

O95248
LFLYRARSAFPYAHR

PPCS

81

Q9HAB8
PAPRHAFEIFRRFYL

CUL3

526

Q13618
RFRFRAFHFLNRFPS

DMBT1

2341

Q9UGM3
YSHFQHLLYRRFAPD

HPS3

286

Q969F9
YLPLFREAFSRRHFQ

PRAMEF2

36

O60811
NRTVAHHFPRLLYFT

CHPF2

121

Q9P2E5
PFHERFFRFLLRKLY

GGCX

676

P38435
RRYRPFARSHSFRFH

TRPM6

1531

Q9BX84
HVHRRFLPFEALSRY

ZFHX2

1501

Q9C0A1
SHARFYFLFHRPLRL

TMEM39A

406

Q9NV64
YLRHVPLRRVHLFTF

SLC4A4

941

Q9Y6R1
RLFRFPYYLSRHRLS

ZNF579

51

Q8NAF0
HLTRRDIRHNFSPYF

PIGM

261

Q9H3S5
RHFPFKALHFYLIRA

ART5

126

Q96L15